Compounding Chemotherapy Market Research, 2034
The global compounding chemotherapy market size was valued at $5.3 billion in 2024, and is projected to reach $9.8 billion by 2034, growing at a CAGR of 6.4% from 2025 to 2034. The compounding chemotherapy market is driven by an increase in demand for personalized cancer treatments, advancements in compounding pharmacy technologies, and rise in number of cancers diagnosed globally. For instance, an article published by the National Center for Biotechnology and Information (NCBI), in 2025, 2 million new cancer cases projected to occur in the U.S. This increasing cancer cases has escalated the demand for safe, accurate, and efficient chemotherapy drug preparation and delivery systems, thus substantially driving the need of compounding chemotherapy devices.
Compounding chemotherapy refers to the process of customizing and preparing chemotherapy medications tailored to an individual patient's specific needs. This involves combining, mixing, or altering the ingredients of various chemotherapy drugs to create a formulation that suits a patient's unique medical condition, dosage requirements, and potential allergies. Compounded chemotherapy medications are typically prepared by licensed pharmacists in specialized compounding pharmacies, ensuring that the drugs are precise, safe, and effective.
Key Takeaways
On the basis of dose type, the chemotherapeutic segment dominated the compounding chemotherapy market share in 2024 and is anticipated to be the fastest-growing segment during the forecast period.
On the basis of compounding type, the pharmaceutical dosage alteration segment dominated the global market in 2024. However, the currently unavailable pharmaceutical manufacturing segment is anticipated to be the fastest-growing segment during the forecast period.
On the basis of delivery type, the gravimetric automated compounding segment dominated the global market in 2024 and is anticipated to be the fastest-growing segment during the forecast period.
On the basis of sterility, the sterile segment dominated the global market in 2024 and is anticipated to be the fastest-growing segment during the forecast period.
On the basis of technology, with robotic arm segment dominated the global market in 2024 and is anticipated to be the fastest-growing segment during the forecast period.
Region wise, North America dominated the market in terms of revenue in 2024. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Market Dynamics
According to compounding chemotherapy market analysis factors driving the growth of the market are increase in demand for personalized cancer care and advancements in compounding pharmacy practices. One of the primary drivers of this market growth is the rise in the prevalence of cancer worldwide. The surge in cancer incidences fuels the need for more customized and effective treatments, which has led to an expansion in the compounding chemotherapy market.
The increasing demand for personalized medicine plays a crucial role in compounding chemotherapy market growth. Personalized chemotherapy treatments are designed to cater to the specific genetic makeup, health conditions, and preferences of individual patients. Traditional chemotherapy treatments may not always be suitable for all patients, either due to side effects or ineffective outcomes. Compounding pharmacies offer a solution by customizing drug formulations to meet individual requirements, such as adjusting drug doses, combining multiple drugs, or altering drug delivery methods to improve efficacy and reduce side effects.
This ability to tailor treatments has become particularly important as patients seek more targeted therapies that are better suited to their unique cancer profiles.
In addition, advancements in compounding pharmacy technology have also been pivotal in driving growth of compounding chemotherapy market size.
According to compounding chemotherapy market forecast analysis the development of specialized equipment, better-quality ingredients, and improved compounding techniques has significantly contributed in growing adoption of compounding chemotherapy as it ensures the safety, accuracy, and consistency of compounded chemotherapy treatments. Regulatory support and increasing standardization in compounding practices have further reinforced the markets growth.
In many regions, regulatory authorities have put frameworks in place to monitor and ensure the safety and effectiveness of compounded medications, providing confidence to both healthcare providers and patients. However, the high cost of specialized compounding equipment and skilled professionals might restrain the compounding chemotherapy market growth.
Compounding pharmacies require advanced technology and well-trained staff to prepare chemotherapy medications, which can be expensive. Smaller or less-equipped compounding pharmacies may struggle to compete with larger, more established players, limiting market growth potential.
On the other hand, advancements in technology within compounding pharmacies offer new opportunities for growth. The continuous improvement of compounding equipment, such as automated systems and advanced sterilization techniques, ensures higher accuracy and consistency in drug formulations.
This, in turn, reduces the risk of contamination or errors, improving the safety profile of compounded chemotherapy drugs and increasing confidence among healthcare providers and patients. The development of more efficient and cost-effective compounding methods could also help reduce the overall cost of chemotherapy treatments, making them more accessible to a wider range of patients.
Segmental Overview
The compounding chemotherapy industry is segmented on the basis of dose type, compounding type, delivery method, sterility, technology, and region. By dose type, the market is classified into chemotherapeutic and non-chemotherapeutic. By compounding type, the market is classified into pharmaceutical ingredient alteration, currently unavailable, pharmaceutical manufacturing, and pharmaceutical dosage alteration. By delivery method, the market is classified into gravimetric automated compounding devices, and volumetric automated compounding devices.
By sterility, the market is classified into sterile and non-sterile. By technology, the market is segmented into with robotic arm and without robotic arm. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
By Dose Type
The chemotherapeutic segment dominated the compounding chemotherapy market share in 2024 and is anticipated to register the highest CAGR during the forecast period. This is attributed to increase in demand for personalized cancer treatments, advancements in drug formulation technologies, and the rising prevalence of cancer worldwide. In addition, the ability to tailor chemotherapy drugs to individual patient needs drives the adoption of compounded chemotherapeutic solutions.
By Compounding Type
The pharmaceutical dosage alteration segment dominated the market in terms of revenue in 2024, attributed to the growing need for customized drug doses that cater to individual patient requirements. This segment benefits from the increasing prevalence of conditions that require specific dosage adjustments, such as pediatric and geriatric patients or those with comorbidities.
However, acccording to compounding chemotherapy market opportunity analysis currently unavailable pharmaceutical manufacturing segment is expected to register the highest CAGR during the forecast period. This is attributed to rising demand for treatments that are not commercially available or discontinued, prompting healthcare providers to seek compounded alternatives. In addition, advancements in compounding technologies and regulatory support for manufacturing unapproved or unavailable drugs create opportunities for this segment to cater to unmet patient needs, further driving its growth.
By Delivery Method
The gravimetric automated compounding device segment dominated the market in terms of revenue in 2024 and is expected to register the highest CAGR during the forecast period. This is attributed to its ability to ensure high accuracy and consistency in drug formulation. These devices provide precise measurements, reduce human error, and improve the overall safety and efficiency of the compounding process.
By Sterility
The sterile segment dominated the market in terms of revenue in 2024 and is expected to register the highest CAGR during the forecast period. This is attributed to an increase in demand for sterile compounded medications, which are critical for ensuring patient safety, particularly in chemotherapy treatments. The growing focus on preventing infections, combined with stringent regulatory requirements for sterile drug preparation, has fueled the adoption of sterile compounding practices.
By Technology
The with robotic arm segment dominated the market in terms of revenue in 2024 and is expected to register the highest CAGR during the forecast period. This is attributed to increase in precision, efficiency, and speed that robotic arms offer in the compounding process. Robotic systems reduce human error, enhance drug accuracy, and streamline workflows, making them particularly valuable in high-volume compounding environments. Their ability to ensure consistent, high-quality compounded medications has driven their growing adoption.
By Region
The compounding chemotherapy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in terms of revenue in 2024. This is attributed to the rise in prevalence of cancer, strong healthcare infrastructure, and advanced medical technologies in the region. In addition, the increasing demand for personalized medicine, regulatory support for compounded drugs, and a well-established network of compounding pharmacies contribute to the region's market leadership. The presence of major pharmaceutical companies and the rising adoption of innovative compounding technologies further enhance market growth in North America.
Asia-Pacific is expected to grow at the highest rate during the forecast period owing to rapidly expanding healthcare infrastructure, increasing cancer prevalence, and rising awareness of personalized treatment options. In addition, improvements in compounding pharmacy technologies, coupled with a growing patient population and increased healthcare access in emerging economies, are driving market growth in the region. The demand for cost-effective and customized chemotherapy treatments also contributes to the strong growth prospects in Asia-Pacific.
Competition Analysis
Major key players that operate in the global compounding chemotherapy market are ATS Corporation, Simplivia, Dedalus S.p.A., EQUASHIELD, ARxIUM, Grifols, S.A., Biovalley Group S.p.A., Omnicell Inc., Kapsam Health Products, and Loccioni. Key players operating in the market have adopted acquisition, product launch and partnership as their key strategies to expand their product portfolio.
Recent Developments in the Compounding chemotherapy Industry
- In March 2024, Simplivia introduced SmartCompounders, an advanced robotic chemotherapy automation system integrated with the Chemfort Closed System Drug-Transfer Device (CSTD). SmartCompounders is designed to enhance the drug compounding process by improving precision, efficiency, and safety, thereby reducing the risk of hazardous drug exposure for healthcare professionals. This modular, plug-and-play solution offers a compact design with high throughput, aiming to revolutionize pharmacy workflows.
- In October 2022, Nordic Capital partnered with Equashield, a global leader in hazardous drug compounding technologies, by becoming a significant shareholder. Equashield specializes in closed system transfer devices (CSTDs) and automated compounding solutions, including AI-powered systems. The partnership aims to accelerate Equashield's growth and global leadership in safe drug compounding technologies.
- In October 2022, Pharmoduct, an automated chemotherapy compounding solution, is set to be introduced in Australia and New Zealand. Byron Phillips, Dedalus ANZ's senior principal for digital healthcare strategy, highlighted that this technology aims to revolutionize the oncology workflow by optimizing the cancer drug ordering, preparation, and receipting processes across the supply chain.
- In January 2021, Simplivia Healthcare Ltd. announced the acquisition of a 70% stake in Novamed Ltd., an Israeli diagnostic company specializing in innovative diagnostic platforms and test kits. Novamed employs approximately 100 professionals, including researchers and engineers, at its advanced manufacturing facility.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding chemotherapy market analysis from 2024 to 2034 to identify the prevailing compounding chemotherapy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the compounding chemotherapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global compounding chemotherapy market trends, key players, market segments, application areas, and market growth strategies.
Compounding Chemotherapy Market, by Dose type Report Highlights
| Aspects | Details |
 Market Size By 2034 | USD 9.8 billion |
 Growth Rate | CAGR of 6.4% |
 Forecast period | 2024 - 2034 |
 Report Pages | 364 |
 By Technology |
|
 By Dose type |
|
 By Compounding Type |
|
 By Delivery method |
|
 By Sterility |
|
 By Region |
|
 Key Market Players | Biovalley Group S.p.A., Loccioni, Simplivia, Kapsam Health Products, Dedalus S.p.A., ATS Corporation, EQUASHIELD, Grifols, S.A., Omnicell Inc., ARxIUM |
The forecast period for compounding chemotherapy market is 2025 to 2034.
The total market value of compounding chemotherapy market was $5.3 billion in 2024.
The market value of compounding chemotherapy market is projected to reach $9.8 billion by 2034.
The base year is 2024 in compounding chemotherapy market.
Top companies such as EQUASHIELD,Grifols, S.A., Dedalus S.p.A., and ATS Corporation held a high market position in 2024.
Loading Table Of Content...
Loading Research Methodology...
